NLRP3 and diabetic cardiomyopathy: Furthermore, the treatment of type two diabetes mellitus model mice with 100 mg/kg/day ticagrelor for 12 weeks attenuated the progression of diabetic cardiomyopathy and reduced the expression levels of NLRP3, caspase-1, and GSDMD-N in the myocardium (Chen et al., 2020).